Advertisement

Advertisement

KTTA Stock Latest News

Pasithea Therapeutics announces amendments to PAS-004 clinical study

The FlyPasithea Therapeutics announces amendments to PAS-004 clinical study

Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA

PremiumThe Fly

Pasithea Therapeutics granted Orphan Drug Designation for PAS-004 by FDA

27d ago

Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

PremiumThe Fly

Pasithea gets orphan status for treatment of amyotrophic lateral sclerosis

1M ago

Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained

PremiumRatings

Pasithea Therapeutics: Buy Rating Reiterated on PAS-004 Upside Potential and Strong Cash Runway; $3 Price Target Maintained

1M ago

Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives

PremiumCompany Announcements

Pasithea Therapeutics Appoints New CMO, Updates Equity Incentives

2M ago

Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer

PremiumThe FlyPasithea Therapeutics appoints Kartik Krishnan as chief medical officer

2M ago

Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004

The Fly

Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004

2M ago

Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice

Company Announcements

Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice

4M ago

Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization

PremiumCompany Announcements

Pasithea Therapeutics Shareholders Approve Expanded Equity Authorization

5M ago

Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway

PremiumRatings

Pasithea Therapeutics: Buy Rating on Differentiated PAS-004, 2026 Clinical Catalysts, and Strengthened Cash Runway

6M ago

Pasithea Therapeutics provides updated timeline on PAS-004 programs

PremiumThe Fly

Pasithea Therapeutics provides updated timeline on PAS-004 programs

6M ago

Pasithea Therapeutics Regains Nasdaq Compliance

PremiumCompany Announcements

Pasithea Therapeutics Regains Nasdaq Compliance

7M ago

Pasithea Therapeutics initiated with a Buy at H.C. Wainwright

PremiumThe FlyPasithea Therapeutics initiated with a Buy at H.C. Wainwright

7M ago

3 Penny Stocks to Watch Now, 12/2/25

Market News

3 Penny Stocks to Watch Now, 12/2/25

7M ago

Pasithea Therapeutics Completes $60M Public Offering

Company Announcements

Pasithea Therapeutics Completes $60M Public Offering

7M ago

Pasithea Therapeutics prices 80M shares at 75c in public offering

PremiumThe Fly

Pasithea Therapeutics prices 80M shares at 75c in public offering

7M ago

3 Penny Stocks to Watch Now, 11/27/25

PremiumMarket News

3 Penny Stocks to Watch Now, 11/27/25

7M ago

Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004

PremiumCompany Announcements

Pasithea Therapeutics Reports Positive Phase 1 Data for PAS-004

7M ago

Pasithea Therapeutics announces $1M award by ALS Association

PremiumThe Fly

Pasithea Therapeutics announces $1M award by ALS Association

7M ago

Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

PremiumThe FlyPasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004

7M ago

Pasithea says tablet PK exposure increases proprtionally with dose increase

The Fly

Pasithea says tablet PK exposure increases proprtionally with dose increase

7M ago

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

Market News

Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!

7M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >